Market Closed -
Nasdaq
21:00:00 27/06/2024 BST
5-day change
1st Jan Change
25.72
USD
+0.27%
-1.00%
+13.50%
Anika Therapeutics, Inc. Announces Resignation of Dana Alexander as Chief Operations Officer, Effective January 12, 2018
January 02, 2018 at 09:05 pm
Anika Therapeutics, Inc. announced that On December 27, 2017, Dana Alexander resigned his role as Chief Operations Officer effective January 12, 2018.
Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics
05-30
CI
Anika Therapeutics Approves $40 Million Share Repurchase Program
05-28
MT
Anika Therapeutics, Inc. announces an Equity Buyback for $40 million worth of its shares.
05-28
CI
Anika Therapeutics, Inc. Announces Board Changes
05-28
CI
Anika Therapeutics, Inc. authorizes a Buyback Plan.
05-27
CI
Transcript : Anika Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023.
05-08
CI
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09
05-08
MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, vs. Street Est of $39.1M
05-08
MT
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024
05-08
CI
Anika Therapeutics, Inc. Announces Management Changes, Effective June 3, 2024
05-08
CI
Anika Therapeutics, Inc. Announces CFO Changes
05-08
CI
Anika Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Anika Therapeutics, Inc.'s Equity Buyback announced on April 13, 2023 has expired.
04-11
CI
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023.
03-15
CI
Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating
03-14
MT
Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
03-13
Anika Therapeutics Swings to Q4 Earnings As Revenue Rises; to Cut 9% Workforce
03-13
MT
Anika Therapeutics Guides For FY 2024 Revenue of $168-$173 Million, vs CIQ Analyst Consensus of $179 Million
03-13
MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q4 EPS $0.05, vs. Street Est of $-0.23
03-13
MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q4 Revenue $43M, vs. Street Est of $41.4M
03-13
MT
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024
03-13
CI
Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-13
CI
Anika Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-13
CI
Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates
03-07
RE
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
More about the company
Last Close Price
25.72
USD
Average target price
31
USD
Spread / Average Target
+20.53%
Consensus
1st Jan change
Capi.
+13.50% 382M +3.57% 94.76B -3.68% 37.58B -11.61% 33.3B +74.21% 27.92B -13.40% 15.85B -2.29% 13.79B -12.21% 11.51B +188.83% 10.9B -53.94% 9.27B
Biopharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ANIKA THERAPEUTICS, INC. 
